Taking a Look at the Operational Data for Aurinia Pharmaceuticals Inc. (AUPH)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is an interesting stock at present. Now trading with a market value of 611.65M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For AUPH, the company currently has 265.48 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 292.99 million in total assets, balanced by 62.72 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Aurinia Pharmaceuticals Inc. (AUPH) saw -12.86 million in free cash flow last quarter, representing a quarterly net change in cash of 210.98 million. Perhaps most importantly where cash movements are concerned, the company saw about -12.86 million in net operating cash flow.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 41,027 in total revenues. That represents a quarterly year/year change in revenues of 0.00 in sequential terms, the (AUPH) saw sales decline by 0.00.

But what about the bottom line? After all, that’s what really matters in the end. Aurinia Pharmaceuticals Inc. (AUPH) is intriguing when broken down to its core data. The cost of selling goods last quarter was 481,735, yielding a gross basic income of -440,708 . For shareholders, given the total diluted outstanding shares of 56.68 million, this means overall earnings per share of -1.22. Note, this compares with a consensus analyst forecast of -0.13 in earnings per share for its next fiscal quarterly report.

Is Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.61 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Aurinia Pharmaceuticals Inc..

Previous ArticleNext Article

Related Post

What do Insider Trends Have to Say About Jaguar He... Recent insider trends for Jaguar Health, Inc. (NASDAQ:JAGX) have caught the attention of investors. Analysts study insider data to get a sense of sens...
What do Insider Trends Have to Say About Twenty-Fi... Recent insider trends for Twenty-First Century Fox, Inc. (NASDAQ:FOXA) have caught the attention of investors. Analysts study insider data to get a se...
What the Insider Data Suggests About Chegg, Inc. (... Recent insider trends for Chegg, Inc. (NYSE:CHGG) have caught the attention of investors. Insider data is useful because it can reveal what a company’...
Are Investors Buying or Selling MGM Resorts Intern... Recent insider trends for MGM Resorts International (NYSE:MGM) have caught the attention of investors. Patters in insider activity can help analysts f...
Should You Buy Las Vegas Sands Corp. (LVS) or SINA... Las Vegas Sands Corp. (NYSE:LVS) shares are up more than 12.45% this year and recently decreased -1.09% or -$0.86 to settle at $78.14. SINA Corporatio...

Leave a Reply

Your email address will not be published.